ASX ANNOUNCEMENT

Lumos Secures Distribution for FebriDx® in Portugal

MELBOURNE, Australia (19 November 2026) – Lumos Diagnostics Holdings Ltd (ASX:LDX, "Lumos" or the "Company") a leader in rapid, point-of-care diagnostic technologies, is pleased to announce that it has executed a new non-exclusive distribution agreement with Magnamed LDA ("Magnamed") for the sale of FebriDx® in Portugal.

Magnamed is a Portuguese medical device distributor that supplies Primary Care, Urgent Care and Hospitals with a range of medical equipment and consumables. Established in 1996, the company represents a number of leading international healthcare brands and provides product support and servicing across Portugal.

Supported by a team of sales specialists, the company services over 300 customers in Portugal. Magnamed's portfolio brings together state of the art technologies providing comprehensive healthcare solutions in the public and private medical environment.

Magnamed has placed an initial stocking order to support immediate availability of FebriDx® for its customers. The agreement will enable Magnamed to distribute FebriDx® into Primary Care, Urgent Care and Hospitals across the Portuguese market, supported by its established logistics network and customer relationships.

Lumos continues to build a broad European distribution network for FebriDx®, with existing agreements already in place across multiple geographies, including the UK, Greece, Romania, Baltics and the Netherlands, Spain & Portugal. The addition of Alpha Medical in July 2026 further strengthened this footprint, and the appointment of Magnamed now broadens Lumos' European reach within Portugal. These partnerships support Lumos' strategy of expanding access to FebriDx® through experienced regional distribution partners across Europe.

Commenting on the announcement, Doug Ward, Managing Director of Lumos Diagnostics said*: "We are pleased to further expand our European distribution network with Magnamed in Portugal. Building on our existing relationships across the region, this partnership will help broaden access to FebriDx® and support our continued commercial growth across Europe."*

-Ends-

This announcement has been approved by the Lumos Disclosure Committee.

About Lumos Diagnostics

Lumos Diagnostics specializes in rapid and complete point-of-care diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded point-of-care tests that target infectious and inflammatory diseases.

For more information visit lumosdiagnostics.com.

Forward-Looking Statements

This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.

Media Contacts:
Haley Chartres – Australia
H^CK Director
haley@hck.digital
+61 423 139 163

Investor Contact:
George Kopsiaftis
IR Specialist, IR Department
ir@lumosdiagnostics.com
+61 409 392 687

Company Registered Office:
Lumos Diagnostics Holdings Ltd
Suite 2, Level 11
385 Bourke Street
Melbourne VIC 3000
info@lumosdiagnostics.com
+61 3 9087 1598